This is an efficacy and safety study of cosibelimab (CK-301) combined with
pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in
participants with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who
have not previously received systemic therapy for advanced disease. Participants will be
randomly assigned in a 2:1 ratio to receive cosibelimab combined with pemetrexed/platinum
(Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators
choice of cisplatin or carboplatin).
The primary hypothesis is that cosibelimab in combination with pemetrexed/platinum
chemotherapy prolongs Overall Survival (OS) compared to pemetrexed/platinum chemotherapy
Metastatic Non-squamous Non Small Cell Lung Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.